LUME-Lung 1 study design

VARGATEF® was tested in LUME-Lung 1 – a multinational, randomised, controlled phase III trial in patients with locally advanced/metastatic recurrent non-small cell lung cancer (NSCLC) after first-line chemotherapy.1,2


Stage IIIB/IV or recurrent NSCLC patients (all histologies)

*Biomarker testing was not performed in LUME-Lung 1


Study endpoints1,2


NSCLC = non-small cell lung cancer;
BID = twice daily;
PO = orally;
ITT = intention to treat;
IV = intravenous



References

1
Reck M et al. Lancet Oncol 2014;15:143–55.
2
VARGATEF® SmPC.